India Cancer Treatment Market to Reach USD 7.12 Billion by 2032, Growing at a CAGR of 14.73% During 2026–2032

The India cancer treatment market was valued at USD 2.88 billion in 2025 and is projected to reach USD 3.12 billion in 2026, further expanding to USD 7.12 billion by 2032. This robust growth is primarily driven by an escalating prevalence of cancer cases and growing healthcare expenditure across the nation. Registering a compound annual growth rate (CAGR) of 14.73% during the 2026–2032 forecast period, the market undergoes significant infrastructural modernization.

Consequently, the country's expanding patient pool, influenced by population growth and shifting lifestyles, creates sustained demand for advanced therapeutics across medical networks. To address this rising health challenge, focused public initiatives such as specialized day care centers and subsidized distribution channels are drastically enhancing therapy access. Moreover, large-scale national screening programs are accelerating early-detection rates, driving greater patient utilization of advanced oncology care platforms.

In parallel, targeted drugs represent the leading treatment category within the domestic oncology ecosystem. The segment's market leadership is thoroughly sustained by a profound clinical shift toward precision medicine, biomarker-guided protocols, and the successful rollout of indigenous cellular therapies. As a result, modern therapeutic choices are transitioning away from standardized regimens toward highly individualized, tumour-specific intervention strategies that yield superior patient recovery outcomes.

Furthermore, breast cancer constitutes the dominant segment among specific oncology indications across the marketplace. This prominent position is heavily reinforced by its status as the most prevalent cancer type among women nationwide, combined with the intensifying clinical utilization of specialized targeted biologics. Additionally, expanding domestic manufacturing lines and competitive local pricing structures continue to lower the financial barriers associated with long-term, high-intensity therapeutic interventions.

Regionally, North India continues to dominate the domestic arena, backed by a substantial patient concentration and extensive regional healthcare infrastructure development. The area benefits from expanding state cancer institutes and dedicated clinical facilities that streamline advanced therapeutic delivery. The industry's long-term momentum remains heavily supported by accelerating healthcare accessibility and affordable biosimilar drug penetration, states the comprehensive research report, “India Cancer Treatment Drugs Market Analysis, 2026.”

India Cancer Treatment Market Highlights

The India cancer treatment market size was valued at USD 2.88 billion in 2025 and is projected to reach USD 3.12 billion in 2026, with a long-term target of USD 7.12 billion by 2032. This expansion underscores the escalating disease burden and expanding healthcare investments across the nation.
The industry is expected to expand at a compound annual growth rate (CAGR) of approximately 14.73% during the 2026–2032 forecast period. This rapid progress is accelerated by rising cancer incidence, enhanced early-detection infrastructure, and public reimbursement programs like Ayushman Bharat-PMJAY.
North India holds the leading market share of an estimated 34% in 2026. The region benefits heavily from dense concentrations of specialized treatment facilities, state cancer institutes, and extensive patient clinical coverage.
Targeted Drugs command the drug class market with a leading share of 44% in 2026. The segment remains dominant due to an industry-wide transition toward precision oncology, biomarker-driven treatment approaches, and the increasing commercial availability of advanced biologics.
Breast Cancer leads the category by cancer type with approximately 19% market share in 2026. This dominance is driven by its position as the most prevalent cancer among Indian women, resulting in high patient volumes and extensive adoption of targeted therapeutics like HER2 inhibitors.

India Cancer Treatment Market Segmentation

By Drug Type
- Targeted Drugs
  - Monoclonal
  - Antibodies
  - Others
- Cytotoxic Drugs
  - Alkylating Agents
  - Antimetabolites
  - Others
- Immune Checkpoint Inhibitors
- Hormonal Agents
- Other Drug Types
By Treatment Type
- Targeted Therapy
- Chemotherapy
- Immunotherapy
- Hormonal Therapy
- Radiation Therapy
- Other Treatment Types
By Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Cervical Cancer
- Hematologic/Blood Cancers
- Head & Neck Cancer
- Brain & CNS Cancers
- Skin Cancer
- Others
By Dosage Form
- Solid
  - Tablets
  - Capsules
- Liquid
- Injectable
  - Prefilled Syringes
  - Others
By End-Users
- Hospitals
- Specialty Clinics
- Cancer and Radiation Therapy Centers
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North
- South
- East
- West